China healthcare site visits: higher innovation threshold, more rational BD, verifiable AIDD revenue

Overview

This report summarizes JPMorgan's two-day visit on May 18-19, 2026 to multiple Chinese healthcare companies in Beijing and Shanghai, covering AI drug discovery, biotech, and medtech. The core conclusion is that the sector is showing four positive changes: AI platforms are moving from concept to verifiable commercial revenue and traditional biotech players are more actively integrating AIDD workflows; biotech pipelines are shifting from simple fast-follow to deeper innovation; companies are obtaining financing support and overseas expansion paths through global partnerships, license-out deals, and NewCo structures; and hospitals are accelerating adoption of surgical robots and biomarker-driven oncology treatment regimens.

Core views

JPMorgan is more constructive on the China healthcare sector, believing that innovation quality, business models, and clinical adoption are all improving in parallel. AIDD companies are beginning to show real commercial monetization capability, while traditional biotech firms are also incorporating AI tools into early discovery and screening processes, which may improve R&D efficiency and earnings visibility. On the biotech pipeline side, siRNA, molecular glues, BCL-2 inhibitors, and oral TYK2/TYK2-JAK1/IL-17 inhibitors reflect more differentiated, unmet-needs-driven development. On the BD side, global partnerships and licensing transactions help extend cash runway and reduce the funding pressure of global clinical development. In medtech and oncology, robot installations, remote surgery, NGS testing, PD-1/VEGF, and TROP2 ADC trends all validate continued hospital adoption of advanced technology and precision therapies.

Analysis framework

The report is based on a two-day industry tour, management meetings, and feedback from clinical experts. It organizes industry changes along four main themes: AIDD commercialization, biotech pipeline innovation, BD financing and globalization, and hospital-end technology adoption, supported by cases such as XtalPi, Harbour BioMed, METiS, Deep Intelligent Pharma, Sirius Therapeutics, GluBio, InnoCare, Syneron, and MicroPort MedBot.

Methodology notes

• industry researchCompany visits and management interviews

  Obtaining company strategy, pipeline, commercialization, and operating data through on-site or field visits.

  The report explicitly states that it visited multiple Chinese healthcare companies in Beijing and Shanghai on May 18-19, and based on that formed views on AIDD, biotech, and medtech trends.

• commercialization validationAIDD revenue verifiability

  Assessing whether an AI drug discovery platform has moved from proof of concept into a stage where it can generate revenue and partnership orders.

  The report focuses on XtalPi's US$345 million partnership with Eli Lilly, its AI model and AI agent deployment, and traditional biotech companies integrating AI-native discovery engines into internal pipeline generation.

• pipeline assessmentDifferentiated innovation and unmet medical need

  Evaluating whether a pipeline goes beyond simple fast-follow and can address differentiated clinical needs and new mechanism development.

  The report uses examples such as Sirius Therapeutics' Factor XI siRNA, GluBio's molecular glues, and InnoCare's BCL-2 and oral immune-related inhibitors to illustrate deeper innovation.

• financing and globalizationBD, license-out and NewCo structures

  Reducing the financing burden of independently undertaking global clinical development through partnerships, licensing, and new company structures.

  The report argues that Chinese biotech is treating BD as a standard task, and cases such as Syneron and Harbour BioMed show that collaboration funding and option-fee mechanisms can support cash runway.

• end-market validationHospital adoption and clinical expert feedback

  Using hospital technology adoption and changes in physician treatment decisions to validate industry direction.

  The report cites MicroPort MedBot's robot installation and remote surgery data, as well as feedback from lung cancer experts on NGS, targeted therapies, patient selection, and drug safety.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• China healthcare industry

  industry theme

  Strengths

  AIDD commercialization, pipeline innovation, BD globalization, and hospital technology adoption create multiple positive trends.

  Weaknesses

  The industry still depends on clinical data realization, funding support, and commercial execution.

  Comparison

  Compared with the prior simple fast-follow and concept-driven AI narrative, the report emphasizes a higher innovation threshold and verifiable revenue.

  Risks

  Clinical failures, regulatory changes, tighter financing conditions, lower-than-expected licensing transactions, and slower hospital procurement and adoption.

• XtalPi (2228.HK)

  Representative AIDD commercialization company, not covered

  Strengths

  Expanded into multispecific antibodies, peptides, siRNA, and other modalities, deployed a large number of AI models and AI agents, and reached a US$345 million partnership with Eli Lilly.

  Weaknesses

  The report does not provide earnings forecasts or valuation details.

  Comparison

  Represents the shift of AIDD from pilot projects to core revenue drivers.

  Risks

  Uncertainty in project conversion, sustainability of platform commercialization, and customer concentration risk.

• Harbour BioMed

  Traditional biotech AIDD and BD case, not covered

  Strengths

  Integrates an AI-native discovery engine through Nona Biosciences and emphasizes preclinical licensing and option-fee economics with AstraZeneca and BMS.

  Weaknesses

  Subsequent clinical data are needed to prove the value of the platform and pipeline.

  Comparison

  Represents traditional biotech using AI tools for early discovery and internal pipeline generation.

  Risks

  Uncertainty around preclinical asset licensing progress, partner option exercise, and data readouts.

• METiS (7666.HK)

  AIDD and mRNA platform company, not covered

  Strengths

  Uses AiLNP, AiRNA, and AiTEM platforms to advance internal mRNA drug assets, improve delivery methods, and pursue outlicensing transactions.

  Weaknesses

  As a newly listed company, the report does not disclose mature revenue or profitability data.

  Comparison

  Shows that AI platforms can serve both internal pipelines and external licensing.

  Risks

  Uncertainty around mRNA delivery validation, licensing execution, and commercialization pace.

• InnoCare (9969.HK)

  Innovative biotech case, not covered

  Strengths

  1Q26 revenue grew 38.65%; it has a presence in hematologic oncology and autoimmune diseases; its BCL-2 inhibitor and TYK2, TYK2/JAK1, and IL-17 oral inhibitors have potential future data catalysts.

  Weaknesses

  Several pipelines still require clinical data validation.

  Comparison

  Represents Chinese biotech moving from fast-follow to differentiated disease areas and mechanism development.

  Risks

  Key clinical data may disappoint, competition may intensify, and commercial execution risk remains.

• MicroPort MedBot (2252.HK)

  Medtech and surgical robot case, OW rating

  Strengths

  Maintained guidance for 200 additional robot installations in 2026, and the Toumai Remote system completed 800+ remote surgeries, showing hospital recognition of platform ROI.

  Weaknesses

  The summary does not disclose profitability or cash flow details.

  Comparison

  Compared with drug development companies, its validation points come more from hospital installations, usage frequency, and remote surgery execution.

  Risks

  Hospital procurement cycles, competition, reimbursement, and robot utilization lower than expected.

Key data

• Visit datesMay 18 to 19, 2026The visit covered AIDD, biotech, and medtech companies in Beijing and Shanghai.
• XtalPi and Eli Lilly partnership sizeUS$345 millionThe report says the partnership was reached in November 2025, illustrating that AIDD platform commercialization is moving from pilot projects to a core revenue driver.
• XtalPi AI deploymentHundreds of AI models, 10,000+ AI agentsCovers key drug modalities such as multispecific antibodies, peptides, and siRNA.
• Deep Intelligent Pharma profitability performance1Q26 net profit exceeded full-year 2025 profitThe company uses LLMs and MAS to drive its clinical CRO business.
• Sirius Therapeutics SRSD107Factor XI reduced by 90%-95%The company plans to advance SRSD107 into Phase 3, and the report uses it as a differentiated siRNA pipeline case.
• InnoCare 1Q26 revenue growth38.65%Management believes the company is well positioned in both hematologic oncology and autoimmune diseases.
• Syneron annual R&D burnUS$60-70 millionManagement said the company maintains high R&D efficiency with support from AstraZeneca and Pfizer Ventures.
• MicroPort MedBot 2026 installation guidance200 additional robotsThe report says the company reiterated this guidance.
• Toumai Remote tele-surgery800+ casesThe report believes this data shows that hospitals are recognizing the platform's concrete return on investment.
• MicroPort MedBot price and rating2252.HK / HK$27.30 / OWPrice as of the May 22, 2026 close.

Impact & implications

From an investment perspective, the report suggests that the focus in China healthcare is shifting from simple valuation re-rating toward verifiable commercialization, differentiated R&D, and global BD capabilities. If AIDD can continue to generate partnership revenue, it may improve earnings visibility for both platform companies and biotech firms adopting AI workflows; biotech companies with original mechanisms, key clinical data catalysts, and clear licensing paths are more likely to gain recognition from global capital and pharma companies; and hospital adoption of robots, NGS, and precision therapies provides demand validation for medtech and next-generation oncology drugs. However, clinical safety, real-world survival benefit, funding burn, and BD sustainability remain key constraints.

Risks

• AIDD partnership revenue may not be sustainable, and platform projects face uncertainty from discovery through clinical translation.
• Biotech pipelines still face clinical failure, insufficient efficacy, safety issues, and regulatory approval risks.
• BD, license-out, and NewCo structures depend on the willingness of global pharma partners and capital market conditions, and transaction execution plus cash runway improvement may fall short of expectations.
• Hospital adoption of advanced technology may be affected by budgets, procurement cycles, physician training, reimbursement policy, and real-world ROI validation.
• First-line oncology treatment in particular requires close attention to safety, and clinical experts still regard safety as an important decision criterion.
• The report is an industry site-visit note, and some companies were not covered and lack a full valuation, earnings forecast, and target-price framework.

What to watch

• Whether XtalPi's partnership with Eli Lilly and other AIDD platform orders translate into sustained revenue.
• Harbour BioMed's global Phase 1 data for the CLDN18.2xCD3 TCE and Phase 1 data for the long-acting TSLP mAb.
• Progress of InnoCare's BCL-2 inhibitor as monotherapy and in combination trials in hematologic oncology.
• Future key data catalysts for InnoCare's TYK2, TYK2/JAK1, and IL-17 oral inhibitors.
• The pace of Sirius Therapeutics' SRSD107 Phase 3 advancement and clinical validation of Factor XI siRNA.
• Progress of GluBio's molecular glue projects GLB-005 and GLB-007 in sickle cell disease and beta-thalassemia.
• Sustainability of global partnerships, licensing, and NewCo transactions at Syneron, Harbour BioMed and peers.
• Completion of MicroPort MedBot's 2026 target of 200 additional robot installations and growth in Toumai Remote tele-surgery.
• Survival benefit and safety data for NGS testing, AK112, TROP2 ADCs, and other bispecific antibodies and ADCs in real-world oncology treatment.